<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Unlike the case with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In the current study of 277 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (<z:hpo ids='HP_0000001'>all</z:hpo> R140Q) and 8 IDH1 (6 R132S and 2 R132C) </plain></SENT>
<SENT sid="2" pm="."><plain>Mutational frequency was 4% (2 of 56) in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts, 12% (16 of 130) in refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 14% (2 of 14) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-unclassifiable, 14% (6 of 42) in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>)-1 and 23% (8 of 35) in <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_458'>Normal</z:mpath> karyotype was noted in <z:hpo ids='HP_0000001'>all</z:hpo> but one IDH1-mutated cases and 13 IDH2-mutated cases </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariable analysis identified presence of mutant IDH1 (P=0.0004; hazard ration 4.0, 95% confidence interval 1.9-8.8), revised International Prognostic Scoring System risk category (P&lt;0.0001), and red cell transfusion need (P=0.002) as independent predictors of inferior survival </plain></SENT>
<SENT sid="5" pm="."><plain>In a similar multivariable analysis, mutant IDH1 was the only variable associated with shortened <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (P=0.001; hazard ration 7.0, 95% confidence interval 2.3-20.8) </plain></SENT>
<SENT sid="6" pm="."><plain>The presence of IDH2R140Q did not affect the overall (P=0.54) or <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free (P=0.81) survival </plain></SENT>
<SENT sid="7" pm="."><plain>The current study suggests a powerful adverse prognostic effect for mutant IDH1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>